Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 9/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 9/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6867220 | 0.85 | MAPT (0.47) | CYP1A2CYP2C9CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL6864489 | 0.81 | GABRA2 (0.37) | CYP1A2CYP2C9CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL6870356 | 0.73 | GABRA2 (0.34) | GABRA2GABRB2 | |
| SCHEMBL6869652 | 0.72 | ALDH1A1 (0.53) | CYP1A2CYP2C9CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL6867874 | 0.70 | CDC7 (0.42) | CYP1A2CYP2C9CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL6974502 | 0.64 | GABRA2 (0.45) | GABRA2GABRB2GABRB3GABRPGABRD | |
| SCHEMBL2831553 | 0.64 | MAPT (0.40) | CYP1A2CYP2C9CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL6870981 | 0.63 | GABRA2 (0.61) | GABRA2GABRB2GABRB3GABRPGABRD | |
| SCHEMBL9996686 | 0.63 | PDE2A (0.49) | CYP1A2CYP2C9CYP2C19MAPTKDM4E | |
| SCHEMBL7815528 | 0.63 | GABRA2 (0.47) | GABRA2GABRB2GABRB3GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812241-B2 | FOR PLANTS, HUMANS, VETERINARY MEDICINE | PFIZER INC. | 2004-11-02 | — | — | US | disclosed |
| US-20030130307-A1 | Heterocycles | BANKS BERNARD JOSEPH (GB) | 2003-07-10 | — | — | US | disclosed |
| US-6525079-B2 | Antiparasitic compounds such as 4-(2,2-dibromocyclopropyl)-1-(2,6-dichloro-4-trifluoromethylphenyl)-1,2,3 -triazole | PFIZER INC. | 2003-02-25 | — | — | US | disclosed |
| US-20010005725-A1 | Heterocycles | BANKS BERNARD JOSEPH (GB) | 2001-06-28 | — | — | US | disclosed |
| US-6110958-A | PARASITICIDES | PFIZER INC. (US) | 2000-08-29 | — | — | US | disclosed |
| US-6083965-A | ANTIPARASITIC AGENTS | PFIZER INC (US) | 2000-07-04 | — | — | US | disclosed |
| EP-0957094-A1 | 1-(2-Halogenaryl)azoles as antiparasitic agents | PFIZER INC. (US) | 1999-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130307-A1 | Heterocycles | CYP1A1, CYP2E1, CYP1B1 | CYP1A2 4/4885CYP2C9 24/4885CYP2C19 6/4885 |
| US-20010005725-A1 | Heterocycles | CYP1A1, CYP2E1, CYP1B1 | CYP1A2 4/4885CYP2C9 24/4885CYP2C19 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.